Compare Marvell Technology Inc (MRVL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs TransMedics Group Inc — how do they compare? Marvell Technology Inc trades at $234.11 (market cap $200.91B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Marvell Technology Inc is far larger — about 65.7× TransMedics Group Inc's market cap, and Marvell Technology Inc pays a 0.11% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MRVL | TMDX | |
|---|---|---|
Market Cap | $200.91B | $3.06B |
Sector | Technology | Technology |
52-Week High | $316.43 | $150.42 |
52-Week Low | $66.59 | $61.99 |
Enterprise Value | $202.26B | $3.46B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $225.41, up 0.83% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth projections, with management forecasting $12 billion for fiscal 2026 and $18 billion for 2027. Despite negative net income in recent periods, the company has consistently beaten EPS expectations and maintains strong profitability margins. Technical indicators show bullish moving averages with support at $221 and resistance at $231.
Marvell presents significant growth potential driven by AI chip demand, with an 82% analyst buy rating and $303 consensus price target representing 34% upside. Key risks include intense competition from Broadcom, customer concentration, and high valuation multiples. The October Investor Day could serve as a catalyst for further price appreciation if growth projections are reaffirmed.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
